Global Prurigo Nodularis Therapeutics Market, by Product Type (Corticosteroids, Capsaicin Cream, Antihistamines, Anticonvulsants, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 824.4 million in 2021 and is expected to exhibit a CAGR of 4.2% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
The Prurigo nodularis therapeutics market is expected to witness rapid growth over the forecast period, owing to increasing research and development products.
On, 2018, Menlo Therapeutics Inc., announced the top line result from MTI-103 (ATOMIK), the Phase 2 clinical trial of serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis (AD)
Global Prurigo Nodularis Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe such as U.S., Europe, and India has impacted the financial status of businesses in all sectors. The private healthcare sector is one of the sectors that has been majorly impacted by the pandemic.
The lockdowns in various countries have created an economic burden on the private healthcare sector. Healthcare providers are facing challenges with regards to manpower, equipment, consumables, and other resources to ensure safety of patients with other diseases, and declining outpatient visits, among others.
Moreover, the pandemic has negatively impacted the development, production, and supply of drugs, and affected growth of the healthcare segment of various companies across the globe. This has led to closure of industrial establishments, except manufacturing of essential commodities, thus causing disruption in supply chain of products.
Supply chain and manufacturing activities in India, China, U.S., and others have been disrupted due to global lockdowns. Whereas, countries such as Thailand, Indonesia, Singapore, and others are facing problems with transportation of drugs and medications.
Browse 27 Market Data Tables and 25 Figures spread through 153 Pages and in-depth TOC on “Prurigo Nodularis Therapeutics Market”- Global Forecast to 2028, by Product Type (Corticosteroids, Capsaicin Cream, Antihistamines, Anticonvulsants, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the Global Prurigo Nodularis Therapeutics Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/prurigo-nodularis-therapeutics-market-4509
Key Takeaways of the Global Prurigo Nodularis Therapeutics Market:
- The global prurigo nodularis therapeutics market is expected to exhibit a CAGR of 4.2% over the forecast period, owing to increasing research and development activities by various companies to manufacture drugs for the treatment of prurigo nodularis. For instance, in 2016, Trevi Therapeutics, Inc., a late-stage clinical development company that developed oral Nalbuphine ER for chronic pruritus conditions, announced positive results from its Phase 2 trial for the treatment of moderate to severe prurigo nodularis.
- Among Region, North America region is accounted for the largest market share in 2021. Owing to the presence of major key players in this region such as Pfizer Inc., Celgene Corporation, Johnson & Johnson Services, Inc., and Trevi Therapeutics Inc.
- Key players operating in the global prurigo nodularis therapeutics market Bayer AG, GlaxoSmithKline Plc., Johnson & Johnson Services, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Novartis AG, Celgene Corporation, VYNE Therapeutics Inc., Trevi Therapeutics Inc., Galderma SA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc.
